期刊
BIOORGANIC & MEDICINAL CHEMISTRY
卷 42, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2021.116266
关键词
Anticancer; PCAF; Bioisosterism; Synthesis; Triazoloquinazoline; Apoptosis
The study reported the design and synthesis of triazoloquinazoline derivatives with potential anticancer activity by bioisosteric modification. Compound 22 showed strong cytotoxicity against various human cancer cell lines and exhibited potent PCAF inhibitory effects, especially on the PC3 cell line.
Inhibition of PCAF bromodomain has been validated as a promising strategy for the treatment of cancer. In this study, we report the bioisosteric modification of the first reported potent PCAF bromodomain inhibitor, L-45 to its triazoloquinazoline bioisosteres. Accordingly, three new series of triazoloquinazoline derivatives were designed, synthesized, and assessed for their anticancer activity against a panel of four human cancer cells. Three derivatives demonstrated comparable cytotoxic activity with the reference drug doxorubicin. Among them, compound 22 showed the most potent activity with IC50 values of 15.07, 9.86, 5.75, and 10.79 mu M against HepG2, MCF-7, PC3, and HCT-116 respectively. Also, compound 24 exhibited remarkable cytotoxicity effects against the selected cancer cell lines with IC50 values of 20.49, 12.56, 17.18, and 11.50 mu M. Compounds 22 and 25 were the most potent PCAF inhibitors (IC50, 2.88 and 3.19 mu M, respectively) compared with bromosporine (IC50, 2.10 mu M). Follow up apoptosis induction and cell cycle analysis studies revealed that the bioisostere 22 could induce apoptotic cell death and arrest the cell cycle of PC3 at the G2/M phase. The in silico molecular docking studies were additionally performed to rationalize the PCAF inhibitory effects of new triazoloquinazoline bioisosteres.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据